Your browser doesn't support javascript.
loading
Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function.
Cuadrado, Maria M; Szydlo, Richard M; Watts, Mike; Patel, Nishil; Renshaw, Hanna; Dorman, Jude; Lowdell, Mark; Ings, Stuart; Anthias, Chloe; Madrigal, Alejandro; Mackinnon, Stephen; Kottaridis, Panagiotis; Carpenter, Ben; Hough, Rachael; Morris, Emma; Thomson, Kirsty; Peggs, Karl S; Chakraverty, Ronjon.
Afiliação
  • Cuadrado MM; Anthony Nolan Research Institute, London;.
  • Szydlo RM; Department of Haematology, Imperial College London;.
  • Watts M; Cellular Therapeutics, University College London.
  • Patel N; Department of Hematology, Royal Free London NHS Trust, London.
  • Renshaw H; Department of Hematology, Royal Free London NHS Trust, London.
  • Dorman J; Department of Hematology, University College Hospital NHS Trust, London.
  • Lowdell M; Department of Hematology, University College Hospital NHS Trust, London.
  • Ings S; Cellular Therapeutics, University College London.
  • Anthias C; Anthony Nolan Research Institute, London.
  • Madrigal A; Anthony Nolan Research Institute, London.
  • Mackinnon S; Department of Hematology, University College Hospital NHS Trust, London.
  • Kottaridis P; Department of Hematology, University College Hospital NHS Trust, London.
  • Carpenter B; Department of Hematology, University College Hospital NHS Trust, London.
  • Hough R; Department of Hematology, University College Hospital NHS Trust, London.
  • Morris E; Department of Hematology, University College Hospital NHS Trust; Cancer Institute UCL, London.
  • Thomson K; Department of Hematology, University College Hospital NHS Trust, London.
  • Peggs KS; Department of Hematology, University College Hospital NHS Trust; Cancer Institute UCL, London.
  • Chakraverty R; Department of Hematology, University College Hospital NHS Trust; Cancer Institute UCL, London.
Haematologica ; 105(11): 2639-2646, 2020 11 01.
Article em En | MEDLINE | ID: mdl-33131253
Poor graft function is a serious complication following allogeneic hematopoietic stem cell transplantation. Infusion of CD34+-selected stem cells without pre-conditioning has been used to correct poor graft function, but predictors of recovery are unclear. We report the outcome of 62 consecutive patients who had primary or secondary poor graft function who underwent a CD34+-selected stem cell infusion from the same donor without further conditioning. Forty-seven of 62 patients showed hematological improvement and became permanently transfusion and growth factor-independent. In multivariate analysis, parameters significantly associated with recovery were shared CMV seronegative status for recipient/donor, the absence of active infection and matched recipient/donor sex. Recovery was similar in patients with mixed and full donor chimerism. Five -year overall survival was 74.4% (95% CI 59-89) in patients demonstrating complete recovery, 16.7% (95% CI 3-46) in patients with partial recovery and 22.2% (CI 95% 5-47) in patients with no response. In patients with count recovery, those with poor graft function in 1-2 lineages had superior 5-year overall survival (93.8%, 95% CI 82-99) than those with tri-lineage failure (53%, 95% CI 34-88). New strategies including cytokine or agonist support, or second transplant need to be investigated in patients who do not recover.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro Idioma: En Ano de publicação: 2020 Tipo de documento: Article